A study demonstrates that using artificial intelligence to assist pathologists in prostate biopsy reporting improves diagnostic consistency.
Impact on Laboratory Efficiency
The study found that AI successfully identified subtle cancerous lesions and helped pathologists adjust tumor grading. Laboratories using AI experienced faster diagnostic turnaround times, with patients receiving results almost a day sooner. The software also reduced the need for additional immunohistochemistry staining, offering efficiency and cost savings for digital pathology labs.
Diagnostic Tools and Authorization
The Paige Prostate Suite, comprising applications for detecting and grading prostate cancer, has received FDA authorization and CE-marked/UKCA-marked status for clinical use with specific imaging equipment. Some applications are currently for research use only. The Articulate Pro study, led by Professor Clare Verrill, investigated the technology's impact on clinical decisions and resource utilization across NHS trusts.
